Levofloxacin for the treatment of community-acquired pneumonia.

about

Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization.Permeability and concentration of levofloxacin in epithelial lining fluid in patients with lower respiratory tract infections.

P2860

Q42042948-E625CE24-658D-4596-93F6-2C31B1631C30 Q43207762-472A774F-50A8-4881-9110-8949634F2EDE

P2860

Levofloxacin for the treatment of community-acquired pneumonia.

Item

http://www.wikidata.org/entity/Q36670872

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Levofloxacin for the treatment of community-acquired pneumonia.

@ast

Levofloxacin for the treatment of community-acquired pneumonia.

@en

type

Item

label

Levofloxacin for the treatment of community-acquired pneumonia.

@ast

Levofloxacin for the treatment of community-acquired pneumonia.

@en

prefLabel

Levofloxacin for the treatment of community-acquired pneumonia.

@ast

Levofloxacin for the treatment of community-acquired pneumonia.

@en

P1476

Levofloxacin for the treatment of community-acquired pneumonia.

@en

P2093

Joseph P Lynch

http://www.w3.org/2001/XMLSchema#string

Thomas M File

http://www.w3.org/2001/XMLSchema#string

P2860

A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin

A critical review of the fluoroquinolones: focus on respiratory infections

Structure-activity and structure-side-effect relationships for the quinolone antibacterials

In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin

Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies.

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.

Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.

Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults

In vitro activities of newer quinolones against bacteroides group organisms.

P304

725-742

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14787210.4.5.725

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

George G Zhanel

P577

2006-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6659297

http://www.w3.org/2001/XMLSchema#string

P698

17140350

http://www.w3.org/2001/XMLSchema#string

P921

Bruschtfiewer

Levofloxacin for the treatment of community-acquired pneumonia.

about

P2860

P2860

Levofloxacin for the treatment of community-acquired pneumonia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921